

# George J Weiner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8821464/publications.pdf>

Version: 2024-02-01

146  
papers

10,159  
citations

39113

52  
h-index

40945

97  
g-index

150  
all docs

150  
docs citations

150  
times ranked

14571  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab: Mechanism of Action. <i>Seminars in Hematology</i> , 2010, 47, 115-123.	1.8	629
2	CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 9305-9310.	3.3	569
3	Building better monoclonal antibody-based therapeutics. <i>Nature Reviews Cancer</i> , 2015, 15, 361-370.	12.8	558
4	Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 10833-10837.	3.3	479
5	Cancer Immunotherapy Comes of Age. <i>Journal of Clinical Oncology</i> , 2011, 29, 4828-4836.	0.8	411
6	Cancer and Inflammation: Promise for Biologic Therapy. <i>Journal of Immunotherapy</i> , 2010, 33, 335-351.	1.2	293
7	Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. <i>Journal of Clinical Oncology</i> , 1997, 15, 1143-1149.	0.8	280
8	Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge. <i>Cancer Research</i> , 2015, 75, 5-10.	0.4	261
9	Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs. <i>Journal of Immunology</i> , 2001, 167, 4878-4886.	0.4	221
10	Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. <i>Blood</i> , 2006, 108, 2648-2654.	0.6	215
11	Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma. <i>Blood</i> , 1997, 89, 2994-2998.	0.6	184
12	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	0.8	184
13	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
14	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 868-876.	9.4	179
15	NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. <i>Blood</i> , 2008, 111, 1456-1463.	0.6	172
16	Bispecific antibodies in cancer therapy. <i>Current Opinion in Immunology</i> , 1999, 11, 558-562.	2.4	159
17	Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. <i>Blood</i> , 2010, 115, 1156-1165.	0.6	150
18	A Polymorphism in the Complement Component <i>C1qA</i> Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 6697-6703.	3.2	149

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
20	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2006, 29, 558-568.	1.2	145
21	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3512.	0.8	144
22	B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. <i>Blood</i> , 2006, 108, 2712-2719.	0.6	130
23	Radioimmunoscinigraphy with 111 Indium Labeled Cyt-356 for the Detection of Occult Prostate Cancer Recurrence. <i>Journal of Urology</i> , 1994, 152, 1490-1495.	0.2	129
24	Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. <i>Blood</i> , 2009, 114, 5322-5330.	0.6	129
25	Active choice but not too active: Public perspectives on biobank consent models. <i>Genetics in Medicine</i> , 2011, 13, 821-831.	1.1	127
26	CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. <i>Journal of Immunological Methods</i> , 2005, 304, 88-99.	0.6	120
27	CpG oligodeoxynucleotides as immunotherapy in cancer. <i>Update on Cancer Therapeutics</i> , 2008, 3, 27-32.	0.9	120
28	Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1998, 92, 3730-3736.	0.6	119
29	B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides. <i>Clinical Cancer Research</i> , 2005, 11, 1490-1499.	3.2	118
30	Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. <i>Blood</i> , 2011, 118, 3347-3349.	0.6	117
31	Monoclonal antibody mechanisms of action in cancer. <i>Immunologic Research</i> , 2007, 39, 271-278.	1.3	112
32	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 6168-6174.	3.2	111
33	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	0.6	110
34	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
35	Complement in monoclonal antibody therapy of cancer. <i>Immunologic Research</i> , 2014, 59, 203-210.	1.3	94
36	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94

#	ARTICLE	IF	CITATIONS
37	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
38	Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. <i>Current Opinion in Hematology</i> , 2000, 7, 168-173.	1.2	91
39	Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. <i>Leukemia</i> , 2003, 17, 314-318.	3.3	90
40	Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. <i>Journal of Leukocyte Biology</i> , 2005, 77, 378-387.	1.5	90
41	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 211-217.	0.6	82
42	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. <i>Cancer Discovery</i> , 2021, 11, 2998-3007.	7.7	80
43	Potent Antigen-specific Immune Responses Stimulated by Codelivery of CpG ODN and Antigens in Degradable Microparticles. <i>Journal of Immunotherapy</i> , 2007, 30, 469-478.	1.2	78
44	CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. <i>Cancer Research</i> , 2003, 63, 5595-600.	0.4	78
45	APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells. <i>Journal of Immunology</i> , 2000, 165, 6244-6251.	0.4	77
46	Complement and cellular cytotoxicity in antibody therapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 759-768.	1.4	76
47	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
48	The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. <i>Journal of Leukocyte Biology</i> , 2000, 68, 455-63.	1.5	63
49	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. <i>Leukemia and Lymphoma</i> , 2013, 54, 2500-2505.	0.6	58
50	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	5.8	58
51	Biodegradable Microparticles Loaded with Doxorubicin and CpG ODN for In Situ Immunization Against Cancer. <i>AAPS Journal</i> , 2015, 17, 184-193.	2.2	58
52	Humanization and characterization of the anti-HLA-DR antibody 1D10. <i>International Journal of Cancer</i> , 2001, 93, 556-565.	2.3	57
53	A comparative study of the antigen-specific immune response induced by codelivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles**Xue Qing Zhang and Christopher E. Dahle contributed equally to this work.. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 3283-3292.	1.6	57
54	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57

#	ARTICLE	IF	CITATIONS
55	AACR Cancer Progress Report 2013. <i>Clinical Cancer Research</i> , 2013, 19, S1-S98.	3.2	55
56	AACR Cancer Progress Report 2014. <i>Clinical Cancer Research</i> , 2014, 20, S1-S112.	3.2	48
57	CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. <i>Current Opinion in Oncology</i> , 2003, 15, 440-445.	1.1	45
58	Obesity diminishes response to PD-1-based immunotherapies in renal cancer. , 2020, 8, e000725.		45
59	CpG Oligodeoxynucleotides Enhance Monoclonal Antibody Therapy of a Murine Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 57-61.	2.1	39
60	CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 263-267.	6.6	39
61	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. <i>Blood</i> , 2011, 118, 4882-4889.	0.6	37
62	Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. <i>Journal of Immunology</i> , 2020, 204, 1386-1394.	0.4	37
63	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 880-885.	2.0	36
64	Elevated soluble $IL-2R^{\pm}$ , $IL-8$ , and $MIP-1^2$ levels are associated with inferior outcome and are independent of $MIPI$ score in patients with mantle cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, E223-7.	2.0	36
65	Introduction: bispecific antibodies. <i>Journal of Immunological Methods</i> , 2001, 248, 1-6.	0.6	34
66	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and $^{90}Y$ ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 589-593.	2.0	33
67	The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. <i>Immunogenetics</i> , 2006, 58, 1-8.	1.2	32
68	Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 419-425.	1.2	32
69	Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. <i>American Journal of Hematology</i> , 2014, 89, 757-765.	2.0	32
70	<i>In situ</i> immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. , 2020, 8, e000940.		31
71	Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotypic vaccine that mimics carcinoembryonic antigen. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 317-327.	2.0	29
72	Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. <i>Seminars in Oncology</i> , 2003, 30, 476-482.	0.8	28

#	ARTICLE	IF	CITATIONS
73	Mitochondria control of cell death induced by anti-HLA-DR antibodies. <i>Leukemia</i> , 2003, 17, 1357-1365.	3.3	28
74	CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotypic antibody-based vaccine strategy in CEA transgenic mice. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 515-527.	2.0	28
75	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 998-1000.	2.0	28
76	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	2.0	28
77	Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. , 1998, 77, 251-256.		27
78	Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity. <i>Leukemia</i> , 2005, 19, 759-766.	3.3	27
79	Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, e595-e595.	2.8	27
80	Acute Promyelocytic Infiltration of the Optic Nerve Treated by Oral Trans-retinoic Acid. <i>Ophthalmology</i> , 1992, 99, 1463-1467.	2.5	26
81	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	0.8	24
82	Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy. <i>Leukemia and Lymphoma</i> , 1995, 16, 199-207.	0.6	22
83	Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1187-1197.	0.7	21
84	Monoclonal antibody therapy of B cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 375-385.	1.4	20
85	Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. <i>Leukemia and Lymphoma</i> , 2015, 56, 2373-2378.	0.6	20
86	CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 193-194.	6.6	19
87	Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. <i>Seminars in Oncology</i> , 2002, 29, 93-97.	0.8	18
88	Picking the Optimal Target for Antibody-Drug Conjugates. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e103-e107.	1.8	18
89	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	1.7	17
90	Intestinal Helminths Regulate Lethal Acute Graft-versus-Host Disease and Preserve the Graft-versus-Tumor Effect in Mice. <i>Journal of Immunology</i> , 2015, 194, 1011-1020.	0.4	16

#	ARTICLE	IF	CITATIONS
91	Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. , 2021, 9, e002484.		16
92	CpG oligodeoxynucleotides enhance FcγRI-mediated cross presentation by dendritic cells. International Immunology, 2004, 16, 1091-1098.	1.8	15
93	Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model. ACS Biomaterials Science and Engineering, 2020, 6, 2659-2667.	2.6	15
94	Monoclonal Antibodies in the Treatment of Human B-Cell Malignancies. Leukemia and Lymphoma, 1998, 31, 237-249.	0.6	14
95	Immunostimulatory DNA sequences and cancer therapy. Seminars in Immunopathology, 2000, 22, 107-116.	4.0	14
96	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. Leukemia and Lymphoma, 2015, 56, 434-439.	0.6	14
97	B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. International Immunology, 2014, 26, 383-395.	1.8	13
98	Three Steps to Breaking Immune Tolerance to Lymphoma: A Microparticle Approach. Cancer Immunology Research, 2015, 3, 389-398.	1.6	13
99	Identification of Candidate B-Lymphoma Genes by Cross-Species Gene Expression Profiling. PLoS ONE, 2013, 8, e76889.	1.1	13
100	Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. Journal of Hematology and Oncology, 2021, 14, 204.	6.9	13
101	Immunoscintigraphy with <sup>111</sup> In-satumomab pentetide in patients with colorectal adenocarcinoma. Diseases of the Colon and Rectum, 1994, 37, 129-137.	0.7	12
102	The safety and pharmacokinetics in adult subjects of an intravenously administered <sup>99m</sup> Tc-labeled 17 amino acid peptide (CYT-379). Nuclear Medicine and Biology, 1994, 21, 131-142.	0.3	12
103	Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clinical Cancer Research, 2017, 23, 954-961.	3.2	12
104	Minimally differentiated acute leukemia. Leukemia Research, 1993, 17, 199-208.	0.4	11
105	The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility. Leukemia, 2007, 21, 2354-2355.	3.3	10
106	Essential Components of Cancer Education. Cancer Research, 2015, 75, 5202-5205.	0.4	10
107	Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. , 2020, 8, A2.2-A3.		10
108	T Cell Activation and Cytokine Production in Anti-CD3 Bispecific Antibody Therapy. Stem Cells and Development, 1995, 4, 395-402.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes. <i>Journal of Immunological Methods</i> , 2005, 297, 259-263.	0.6	9
110	Helminth-Induced Production of TGF- $\beta$ 2 and Suppression of Graft-versus-Host Disease Is Dependent on IL-4 Production by Host Cells. <i>Journal of Immunology</i> , 2018, 201, 2910-2922.	0.4	9
111	A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1206-1214.	1.6	9
112	Antibody Therapy of Lymphoma. <i>Advances in Pharmacology</i> , 2004, 51, 229-253.	1.2	8
113	Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. , 2020, , .		8
114	Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLA-2 cells. <i>Immunology</i> , 1996, 87, 271-274.	2.0	7
115	T cells, particularly activated CD4+ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 237-249.	2.0	7
116	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. <i>Blood</i> , 2006, 108, 530-530.	0.6	6
117	Radiolabeled Antibody Imaging of Patients with Potentially Resectable Colorectal Adenocarcinoma. <i>Cancer Investigation</i> , 1994, 12, 111-120.	0.6	5
118	5E10: a prostate-specific surface-reactive monoclonal antibody. <i>Cancer Letters</i> , 1998, 131, 129-136.	3.2	5
119	An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients. <i>Cancer Immunology Research</i> , 2019, 7, 1511-1522.	1.6	5
120	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5
121	Short telomeres in B-CLL: the chicken or the egg?. <i>Blood</i> , 2008, 111, 5756-5756.	0.6	4
122	The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. <i>Scientific Reports</i> , 2021, 11, 1535.	1.6	4
123	T-cell activation induced by anti-CD3 + anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand. <i>Cancer Immunology, Immunotherapy</i> , 1997, 45, 174-179.	2.0	3
124	Measuring Granulocyte and Monocyte Accumulation at Malignant Lymphoma Sites. <i>Journal of Clinical Oncology</i> , 2009, 27, 154-155.	0.8	3
125	Serum Alters the Uptake and Biologic Activity of CpG Oligodeoxynucleotides in B Cell Chronic Lymphocytic Leukemia. <i>Oligonucleotides</i> , 2005, 15, 51-59.	2.7	2
126	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Leukemia and Lymphoma</i> , 2015, 56, 2365-2372.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Immune checkpoint markers and anti-CD20-mediated NK cell activation. Journal of Leukocyte Biology, 2020, 110, 723-733.	1.5	2
128	Activation of NK Cell Responses and Immunotherapy of Cancer. , 2014, , 57-66.		2
129	Persistent thrombocytopenia during remission in acute leukemia does not preclude long-term disease-free survival. American Journal of Hematology, 2002, 71, 236-237.	2.0	1
130	Making a better antibody: all is not lost. Blood, 2010, 115, 5127-5128.	0.6	1
131	Brachytherapy Combined with CpG ODN Enhances Development of a Tumor Antigen-Specific CD8 Response.. Blood, 2004, 104, 4635-4635.	0.6	1
132	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. Blood, 2016, 128, 1104-1104.	0.6	1
133	In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines.. Blood, 2005, 106, 4826-4826.	0.6	1
134	Commentary on "The History of the Development of Vaccines for the Treatment of Lymphoma" Clinical Lymphoma and Myeloma, 2000, 1, 140.	2.1	0
135	Cancer biology: Lost in translation?. Cancer Biology and Therapy, 2004, 3, 688-691.	1.5	0
136	Response: Complement in antibody therapy for lymphoma: both a help and a hindrance?. Blood, 2009, 114, 5568-5568.	0.6	0
137	No Mechanism is an Island. , 2014, , 257-267.		0
138	Academic Cancer Center Phase I Program Development. Oncologist, 2017, 22, 369-374.	1.9	0
139	Quantification of Receptor Occupancy by Ligand"An Understudied Class of Potential Biomarkers. Cancers, 2020, 12, 2956.	1.7	0
140	Monocytes Exposed to Immune Complexes Reduce pDC Type 1 Interferon Response to Vidutolimod. Vaccines, 2021, 9, 982.	2.1	0
141	Cpg Oligodeoxynucleotide-Mediated Effects on B-Cell Chronic Lymphocytic Leukemia In Vitro Are Influenced by Cytogenetic Status and the Presence of Serum.. Blood, 2004, 104, 4828-4828.	0.6	0
142	IL-21 and CpG ODN Are Synergistic in Their Ability To Induce Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells and Benign B1 Cells.. Blood, 2005, 106, 5022-5022.	0.6	0
143	IL-21 Plus CpG ODN Induces Granzyme B-Dependent Induction of Apoptosis in CD5-Positive B Cells Including B-CLL Cells.. Blood, 2006, 108, 2823-2823.	0.6	0
144	Granzyme B Produced by Human Plasmacytoid Dendritic Cells Suppresses T Cell Expansion.. Blood, 2009, 114, 2674-2674.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies Better. Transactions of the American Clinical and Climatological Association, 2015, 126, 87-92.	0.9	0
146	Advances in the management of B-cell lymphomas. Clinical Advances in Hematology and Oncology, 2007, 5, 510-2.	0.3	0